PE20211780A1 - Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp) - Google Patents

Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)

Info

Publication number
PE20211780A1
PE20211780A1 PE2021000596A PE2021000596A PE20211780A1 PE 20211780 A1 PE20211780 A1 PE 20211780A1 PE 2021000596 A PE2021000596 A PE 2021000596A PE 2021000596 A PE2021000596 A PE 2021000596A PE 20211780 A1 PE20211780 A1 PE 20211780A1
Authority
PE
Peru
Prior art keywords
pyrimidinodiona
tetrahydropyrane
thp
cyclic
compounds replaced
Prior art date
Application number
PE2021000596A
Other languages
English (en)
Inventor
Mark Grillo
Brian Kane
Johan Oslob
Min Zhong
Fabienne Thompson
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of PE20211780A1 publication Critical patent/PE20211780A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto que tiene la formula (i) o una sal farmaceuticamente aceptable del mismo, en el que el subindice n es 1 o 2; cada R 1 es un miembro seleccionado del grupo que consiste en fluor, cloro, alquilo opcionalmente sustituido C1-C4, uno de R2a y R2b es fluor y el otro de R2a y R2b es H. Son utiles para el tratamiento de la cardiomiopatia hipertrofica (HCM) y las condiciones asociadas con la hipertrofia ventricular izquierda o la disfuncion diastolica, y/o los sintomas asociados a la misma.
PE2021000596A 2018-10-29 2019-10-28 Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp) PE20211780A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752278P 2018-10-29 2018-10-29
PCT/US2019/058297 WO2020092208A1 (en) 2018-10-29 2019-10-28 Tetrahydropyran (thp)-substituted bicyclic-pyrimidinedione compounds

Publications (1)

Publication Number Publication Date
PE20211780A1 true PE20211780A1 (es) 2021-09-08

Family

ID=68841171

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000596A PE20211780A1 (es) 2018-10-29 2019-10-28 Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)

Country Status (17)

Country Link
US (4) US11034693B2 (es)
EP (1) EP3873904A1 (es)
JP (2) JP7447110B2 (es)
KR (1) KR20210086673A (es)
CN (1) CN113056465A (es)
AR (1) AR116880A1 (es)
AU (1) AU2019373206A1 (es)
BR (1) BR112021008077A2 (es)
CA (1) CA3118293A1 (es)
CL (1) CL2021001083A1 (es)
CO (1) CO2021005540A2 (es)
EA (1) EA202191152A1 (es)
IL (1) IL282740A (es)
MX (1) MX2021004955A (es)
PE (1) PE20211780A1 (es)
SG (1) SG11202104218SA (es)
WO (1) WO2020092208A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276013B2 (en) 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd PI4KIIIBETA inhibitors
CN114149423B (zh) * 2020-09-08 2023-12-12 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114456163B (zh) * 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN116323598A (zh) 2020-11-20 2023-06-23 江苏恒瑞医药股份有限公司 三嗪二酮类衍生物、其制备方法及其在医药上的应用
WO2024026058A1 (en) 2022-07-29 2024-02-01 MyoKardia, Inc. Crystalline forms of (6s,7s)-6-fluoro-7-(2-fluoro-5-methylphenyl)- 3-(tetrahydro-2h-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3- d]pyrimidine-2,4(lh,3h)-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190860A (en) * 2013-06-21 2022-05-12 Myokardia Inc Pyrimidinedione compounds against cardiac conditions
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds

Also Published As

Publication number Publication date
JP2024063091A (ja) 2024-05-10
BR112021008077A2 (pt) 2021-08-03
CA3118293A1 (en) 2020-05-07
WO2020092208A1 (en) 2020-05-07
JP2022506524A (ja) 2022-01-17
US20240025894A1 (en) 2024-01-25
AR116880A1 (es) 2021-06-23
CO2021005540A2 (es) 2021-07-30
US20220106314A1 (en) 2022-04-07
CL2021001083A1 (es) 2021-09-24
US20200165247A1 (en) 2020-05-28
IL282740A (en) 2021-06-30
CN113056465A (zh) 2021-06-29
EP3873904A1 (en) 2021-09-08
MX2021004955A (es) 2021-07-21
EA202191152A1 (ru) 2022-01-19
JP7447110B2 (ja) 2024-03-11
AU2019373206A1 (en) 2021-06-17
KR20210086673A (ko) 2021-07-08
SG11202104218SA (en) 2021-05-28
TW202030189A (zh) 2020-08-16
US11034693B2 (en) 2021-06-15
US20220340569A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
PE20211780A1 (es) Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CY1124737T1 (el) Ανταγωνιστες lpa
SV2017005384A (es) Compuestos aminopirimidinilo
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
UY37073A (es) Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
UY37513A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
PE20180600A1 (es) Inhibidores de metalo-beta-lactamasa
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
CO2021016504A2 (es) Inhibidores de cdk
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
DOP2021000088A (es) Compuestos de azalactam como inhibidores de hpk1
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
PE20212070A1 (es) Moduladores de trex1
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
AR121226A1 (es) Compuestos y usos de estos
CU24550B1 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
CR20170372A (es) Compuestos de benzoxaborol y usos de los mismos
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
PE20230182A1 (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter